Key result
In patients with non-ischemic heart failure, flow-mediated vasodilation was significantly lower in those with preserved ejection fraction compared to reduced ejection fraction (4.12% vs 6.61%, P=0.009), whereas in ischemic heart failure, reactive hyperemia index was lower in reduced ejection fraction (P=0.014).
Why the study?
Vascular endothelial function of both conduit arteries and microvasculature has not been simultaneously assessed in patients with heart failure with reduced or preserved ejection fraction.
Does vascular endothelial function differ between HFrEF and HFpEF in patients with ischemic versus non-ischemic heart disease?
Cross-Sectional (n=88)
No
Does vascular endothelial function differ between HFrEF and HFpEF in patients with ischemic versus non-ischemic heart disease?
Endothelial dysfunction differs between conduit arteries and microvasculature in HFrEF versus HFpEF, and is further influenced by ischemic versus non-ischemic etiology.
Vascular endothelial dysfunction is part of the underlying pathophysiology of heart failure. However, there are no reports in which vascular endothelial function of both conduit arteries and microvasculature was assessed in patients with heart failure. This study was aimed to assess vascular endothelial function separately in heart failure with reduced (HFrEF) and preserved ejection fraction (HFpEF). We performed simultaneous measurement of both flow-mediated vasodilation for endothelial function of conduit arteries and reactive hyperemia-peripheral arterial tonometry for that of microvasculature in 88 consecutive patients with chronic heart failure. In 55 patients with ischemic heart disease as an underlying cause of heart failure, flow-mediated vasodilation value was comparable between the two groups of HFrEF (left ventricular ejection fraction < 50%, n = 31) and HFpEF (left ventricular ejection fraction ≥ 50%, n = 24). Reactive hyperemia index measured by reactive hyperemia peripheral arterial tonometry, however, was lower in HFrEF patients compared to HFpEF patients (P = 0.014). In contrast, among 33 patients with non-ischemic heart disease, the degree of flow-mediated vasodilation was lower in HFpEF patients (n = 18) compared with HFrEF patients (n = 15) (P = 0.009), while reactive hyperemia index was comparable between the two groups. The clinical and pathophysiological significance of endothelial function in heart failure differs between conduit artery and microvasculature, and these differences may contribute to the underlying pathophysiology of HFpEF and HFrEF, as well as in ischemic heart disease and non-ischemic heart disease.
No takes yet. Share an insight, caveat, or question.
Waku et al. (2020) conducted a cross-sectional in Chronic heart failure (n=88). Heart failure with reduced ejection fraction (HFrEF) vs. Heart failure with preserved ejection fraction (HFpEF) was evaluated on Flow-mediated vasodilation (FMD) in patients with non-ischemic heart disease (p=0.009). In patients with non-ischemic heart failure, flow-mediated vasodilation was significantly lower in those with preserved ejection fraction compared to reduced ejection fraction (4.12% vs 6.61%, P=0.009), whereas in ischemic heart failure, reactive hyperemia index was lower in reduced ejection fraction (P=0.014).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: